- Home
- THFF vs CRGX Comparison
THFF vs CRGX Comparison
Compare THFF & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THFF
- CRGX
- Stock Information
- Founded
- THFF 1984
- CRGX 2021
- Country
- THFF United States
- CRGX United States
- Employees
- THFF N/A
- CRGX N/A
- Industry
- THFF Major Banks
- CRGX
- Sector
- THFF Finance
- CRGX
- Exchange
- THFF Nasdaq
- CRGX Nasdaq
- Market Cap
- THFF 625.8M
- CRGX 190.0M
- IPO Year
- THFF N/A
- CRGX 2023
- Fundamental
- Price
- THFF $54.19
- CRGX $4.16
- Analyst Decision
- THFF Buy
- CRGX Hold
- Analyst Count
- THFF 2
- CRGX 7
- Target Price
- THFF $56.50
- CRGX $4.67
- AVG Volume (30 Days)
- THFF 54.1K
- CRGX 586.4K
- Earning Date
- THFF 07-22-2025
- CRGX 08-11-2025
- Dividend Yield
- THFF 3.75%
- CRGX N/A
- EPS Growth
- THFF N/A
- CRGX N/A
- EPS
- THFF 4.63
- CRGX N/A
- Revenue
- THFF $215,577,000.00
- CRGX N/A
- Revenue This Year
- THFF $29.97
- CRGX $57.81
- Revenue Next Year
- THFF $2.84
- CRGX N/A
- P/E Ratio
- THFF $11.75
- CRGX N/A
- Revenue Growth
- THFF 9.26
- CRGX N/A
- 52 Week Low
- THFF $35.62
- CRGX $3.00
- 52 Week High
- THFF $54.63
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- THFF 64.58
- CRGX 45.07
- Support Level
- THFF $51.91
- CRGX $4.33
- Resistance Level
- THFF $54.63
- CRGX $4.36
- Average True Range (ATR)
- THFF 1.18
- CRGX 0.19
- MACD
- THFF 0.23
- CRGX -0.04
- Stochastic Oscillator
- THFF 91.04
- CRGX 21.76
About THFF First Financial Corporation Indiana
First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.